5 completed, 5 unknown, 4 recruiting, 3 terminated. 18 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 18 | Completed 5, Unknown 5, Recruiting 4, Terminated 3, Not yet recruiting 1 |
| Phase 2 | 7 | Unknown 5, Terminated 2 |
Follow Gastric Outlet Obstruction: new trials by email Literature Review of Gastric Outlet Obstruction trials Research Report on Gastric Outlet Obstruction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Axatilimab + CAR-T for High-Risk Lymphoma Axatilimab - Diffuse Large B Cell Lymphoma (DLBCL), Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma | Phase 1 | Not yet recruiting | Northside Hospital, Inc. | 29 | 2026-12-31 | 2026-10-16 |
| Imaging Study of [89Zr]DFO-YS5 for Cancer Detection [89Zr]DFO-YS5, Positron Emission Tomography (PET)-Computerized tomography (CT) - Bladder Cancer, Nerve Sheath Tumor | Phase 1 | Recruiting | Robert Flavell, MD, PhD | 40 | 2026-06-15 | 2026-10-01 |
| Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma C402-CD19-CAR - Diffuse Large B-cell-lymphoma, DLBCL, Nos Genetic Subtypes | Phase 1 | Recruiting | Shanghai Exuma Biotechnology Ltd. | 18 | 2025-03-25 | 2026-09-11 |
| SynKIR-310 for Relapsed/Refractory B-NHL SynKIR-310 - B Cell Lymphoma, NHL, Adult | Phase 1 | Recruiting | Verismo Therapeutics | 36 | 2024-11-01 | 2026-04-14 |
| Study of SGR-1505 in Mature B-Cell Neoplasms SGR-1505 - Mature B-Cell Neoplasm, Non Hodgkin Lymphoma | Phase 1 | Recruiting | Schrödinger, Inc. | 98 | 2023-04-10 | 2026-02-13 |
| Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients Selinexor, R-CHOP Protocol - EBV-Positive Diffuse Large B-Cell Lymphoma, Nos | Phase 1 / Phase 2 | Unknown | Sun Yat-sen University | 54 | 2022-11-01 | 2023-12-14 |
| Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL PD-1 Antibody, Lenalidomide - Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 30 | 2021-03-31 | 2021-03-15 |
| A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms TAS1553 - Acute Myeloid Leukemia, Myeloproliferative Neoplasm | Phase 1 | Terminated | Astex Pharmaceuticals, Inc. | 20 | 2020-12-21 | 2024-08-02 |
| INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas INCB7839 - Glioblastoma Multiforme, Anaplastic Astrocytoma | Phase 1 | Completed | Pediatric Brain Tumor Consortium | 13 | 2020-07-27 | 2026-10-01 |
| Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL Camrelizumab, Apatinib - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 33 | 2020-07-23 | 2021-03-15 |
| Lenalidomide in Combination With CHOP in Patients With Untreated PTCL Lenalidomide, Cyclophosphamide, Doxorubicin - PTCL, NOS, AITL | Phase 1 / Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 91 | 2020-06-10 | 2020-06-16 |
| Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma Toripalimab, Rituximab, R-CHOP Protocol - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 140 | 2020-04-24 | 2022-04-14 |
| SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors Gemcitabine, ribociclib, sonidegib - Anaplastic Astrocytoma, Anaplastic Ependymoma | Phase 1 | Completed | St. Jude Children's Research Hospital | 68 | 2018-03-05 | 2024-05-31 |
| Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies XmAb13676 - B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Completed | Xencor, Inc. | 154 | 2016-10-01 | 2024-11-13 |
| Prophylactic Ethanol Lock Therapy (ELT) in Patients on Home Parenteral Nutrition Ethanol, Heparin Lock, Normal Saline - Catheter-related Bloodstream Infection (CRBSI) Nos, Bloodstream Infection Due to Central Venous Catheter | Phase 1 / Phase 2 | Terminated | Mayo Clinic | 39 | 2014-07-01 | 2017-12-12 |
| Multiple Ascending Dose of BMS-911543 BMS-911543 - Cancer | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 98 | 2011-04-07 | 2019-07-31 |
| Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI) 5-FU, Leucovorin, Irinotecan - Gastro-Intestinal Cancer | Phase 1 | Completed | Bristol-Myers Squibb | 49 | 2010-02-01 | 2014-09-16 |
| Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma BMS-833923, Lenalidomide, Dexamethasone - Advanced Cancer, Various, NOS | Phase 1 | Completed | Bristol-Myers Squibb | 27 | 2009-07-01 | 2016-09-30 |
Pyloric Stenosis, Hypertrophic (18) · Lymphoma, Follicular (5) · Lymphoma, Large B-Cell, Diffuse (5) · Lymphoma, B-Cell (3) · Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Mantle-Cell (3) · Lymphoma, Non-Hodgkin (3) · Recurrence (3) · Waldenstrom Macroglobulinemia (3) · Astrocytoma (2) · Burkitt Lymphoma (2) · Dendritic Cell Sarcoma, Interdigitating (2) · Glioblastoma (2) · Glioma (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2)
Digestive System Diseases (18) · Gastrointestinal Diseases (18) · Pyloric Stenosis (18) · Stomach Diseases (18) · Neoplasms by Histologic Type (11) · Neoplasms (10) · Hemic and Lymphatic Diseases (9) · Immune System Diseases (8) · Immunoproliferative Disorders (8) · Lymphatic Diseases (8) · Lymphoma (8) · Lymphoproliferative Disorders (8) · Disease Attributes (6) · Pathologic Processes (6)
Lenalidomide (3) · Cyclophosphamide (2) · Doxorubicin (2) · R-CHOP protocol (2) · Rituximab (2) · Vincristine (2) · BMS-833923 (1) · Bortezomib (1) · Dexamethasone (1) · Ethanol (1) · Exportin 1 Protein (1) · Filgrastim (1) · Fluorouracil (1) · Gemcitabine (1) · Granulocyte Colony-Stimulating Factor (1)
Bristol-Myers Squibb (3) · Huiqiang Huang (3) · Astex Pharmaceuticals, Inc. (1) · Mayo Clinic (1) · Northside Hospital, Inc. (1) · Pediatric Brain Tumor Consortium (1) · Robert Flavell, MD, PhD (1) · Schrödinger, Inc. (1) · Shanghai Exuma Biotechnology Ltd. (1) · St. Jude Children's Research Hospital (1) · Sun Yat-sen University (1) · The First Affiliated Hospital with Nanjing Medical University (1) · Verismo Therapeutics (1) · Xencor, Inc. (1)
United States (12) · China (6) · France (3) · Canada (2) · Australia (1) · Italy (1) · Moldova (1) · Poland (1) · Romania (1) · South Korea (1) · Spain (1) · Ukraine (1) · United Kingdom (1)
Chet Bohac, PharmD, MD, MSc (1) · Frank G Basile, M.D. (1) · Giles W. Robinson, MD (1) · Huiqiang Huang, Professor (1) · Laura A Johnson, PhD (1) · Liang Huang, MD (1) · Michelle Monje, MD, PhD (1) · Robert Flavell, MD (1) · Ryan Hurt, MD, PhD (1) · Wei Xu, M.D., Ph.D. (1)
PMID 28153605, PMID 28478586, PMID 28576557, PMID 31744509, PMID 35398840, PMID 38182653
2009 (1), UM1CA081457 (1)